Median PFS increased from 1.94 months with single-agent fulvestrant to 5.32 months with the addition of ipatasertib. Patients ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

Transwell assay showing increased invasion in SNB19 and U251 glioma cells transfected with FAM111B-overexpressing lentivirus, compared to controls. Magnification ×20 Study shows FAM111B overexpression ...

Ipatasertib combined with fulvestrant significantly extends progression-free survival in ER-positive, HER2-negative ...

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

Awarding ceremonies to be held on June 10, 2025, at the 16th Annual IMWG Summit in Milano, ItalyMILAN, June 10, 2025 (GLOBE ...

Emerging evidence highlights the critical role of vitamin D3 in cellular aging and immune health, particularly through its ...

Kazia Therapeutics ( ($KZIA) ) just unveiled an update. On June 5, 2025, Kazia Therapeutics announced the dosing of the first patient in a Phase ...

Relay Therapeutics plans to initiate the pivotal Phase 3 ReDiscover-2 (NCT06982521) study of RLY-2608 + fulvestrant in ...